Data & Systems
| Catherine Beaucé
(Chair) |
Sanofi |
France |
| Markus Kaemmerer |
Abbott Products Operations
AG |
Switzerland |
| Jackie Lord |
AstraZeneca |
UK |
| Petra Mannechez |
Bayer Healthcare |
Germany |
| Silke Behrendt |
Boehringer Ingelheim GmbH |
Germany |
| Jacky Gossage |
Glaxosmithkline |
UK |
| Karen Belentani |
Takeda Pharmaceuticals International |
Switzerland |
| Christopher Wooden |
Cegedim Strategic Data |
UK |
| Alan Harrison |
IMS Health |
UK |
| Bridget Wiseman |
IMS Health |
UK |
OBJECTIVES
Ensure databases & systems provide the
best suitable platform to do international secondary market
research through partnership with the major global providers.
ACTIVITIES
- Regular meetings with core providers IMS
HEALTH & CEGEDIM STRATEGIC DATA to discuss their databases
& systems offerings (quality, reliability & service
associated) and main development pathways (meet business data
requirements, address changing market dynamics or make the best use
of latest technologies). They represent a key communication channel
between global secondary data providers and international secondary
market research functions from pharmaco’s. Secondary data quality
& coverage issues are also discussed during those meetings. In
that perspective the Committee focus on audits integrated on IMS
& CSD international databases.
- Share experiences & best practice in
international secondary pharmaceutical market research area using
any type of data : sales, medical or promotional.
- Identify current unmet needs of
international pharmaceutical market research and share them with
Syndicated Data Committee to cooperate on provider research.
The Committee consists of pharmaceutical
international market research representatives and IMS & CSD
representatives. Project teams may be formed to address specific
needs and other providers may be invited to participate whenever
appropriate. The Committee always welcomes new members from
pharmaceutical industry to enlarge its knowledge & experience
sharing.